Director, Global GCP QA

About the role

Structure Therapeutics develops life‐changing medicines for patients using advanced structure‐based and computational drug discovery technology. The company’s platform combines the latest advancements in visualization of molecular interactions, computational chemistry, and data integration to design orally available, superior small molecule medicines that overcome current limitations of biologic and peptide drugs. We are advancing a clinical‐stage pipeline of differentiated treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic, and pulmonary conditions. Structure Therapeutics is led by an experienced group of international drug innovators and financed by top-tier global life sciences investors. The company completed an initial public offering (IPO) in February 2023. With offices in California and Shanghai, Structure Therapeutics has the benefit of being at the center of life science innovation in both the US and China and capitalizing on the strengths of each geographic location.

The Director, Global GCP QA is responsible for governance, compliance oversight, and supporting strategic execution across clinical studies and vendor programs, in compliance with applicable national and international standards, regulations, and guidelines. The position will provide support and promote collaboration internally to ensure all systems; processes, and their outcomes remain compliant. The role will provide expert GCP guidance across global regulatory requirements (FDA, EMA, MHRA, NMPA, PMDA, etc.) and ensure compliance with ICH GCP, FDA, EMA, and other relevant global regulations. The role will collaborate cross-functionally to drive continuous improvement and ensure patient safety and data integrity. This position will report to the Executive Director, Global GCP, QA.

Responsibilities

• Study Quality Oversight Act as the primary GCP QA subject